{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477864483
| image =
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = {{link-en|白细胞介素-6受体|Interleukin-6 receptor|IL-6受体}}
<!-- Clinical data -->
| tradename = Actemra, RoActemra
| Drugs.com = {{drugs.com|monograph|tocilizumab}}
| MedlinePlus = a611004
| licence_EU = yes
| DailyMedID = Tocilizumab
| licence_US = Tocilizumab
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S4
| legal_CA = 
| legal_UK = 
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[静脉注射|静脉注射]]、[[皮下注射|皮下注射]]
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound =  
| metabolism =  
| elimination_half-life = 稳态8至14天（由浓度有所不同）
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 375823-41-9
| ATC_prefix = L04
| ATC_suffix = AC07
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I031V2H011
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02596
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1237022
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6428 | H=9976 | N=1720 | O=2018 | S=42
}}

'''托珠单抗'''（[[国际非专利药品名称|INN]]药名 tocilizumab；又名 atlizumab ；商品名 雅美罗、Actemra）是一种主要治疗[[类风湿关节炎|类风湿关节炎]]和[[幼年特发性关节炎|幼年特发性关节炎]]的[[免疫抑制药|免疫抑制药]]。本药是针对[[白细胞介素-6受体|白细胞介素-6受体]]（IL-6R）的{{link-en|人源化抗体|humanized antibody|人源单克隆抗体}}。[[白细胞介素-6|白细胞介素-6]]（IL-6）是一种[[细胞因子|细胞因子]]，在免疫反应中有重要作用，与许多疾病的发病机制有关，如：[[自体免疫疾病|自体免疫疾病]]、[[多发性骨髓瘤|多发性骨髓瘤]]、[[前列腺癌|前列腺癌]]。本药由[[大阪大学|大阪大学]]与[[中外制药|中外制药]]开发，[[罗氏|罗氏]]于2003年获得本药批准<ref name="2003KPJ">{{Cite web|url=http://www.krankenpflege-journal.com/rheuma/768-die-entwicklung-von-tocilizumab-medizinischer-fortschritt-auf-basis-einer-erfolgreichen-kooperation-von-chugai-und-roche.html|language=de|title=Die Entwicklung von Tocilizumab|trans-title=The development of tocilizumab|author=Markus Harwart|year=2008|publisher=Krankenpflege-Journal|access-date=2016-04-30|archive-date=2018-10-15|archive-url=https://web.archive.org/web/20181015051035/http://www.krankenpflege-journal.com/rheuma/768-die-entwicklung-von-tocilizumab-medizinischer-fortschritt-auf-basis-einer-erfolgreichen-kooperation-von-chugai-und-roche.html|dead-url=yes}}</ref>，且于2021年6月在美国获得了用于治疗[[2019冠状病毒病|2019冠状病毒病]]的[[紧急使用授权|紧急使用授权]]<ref>{{cite web|date=June 2021|title=Tocilizumab Emergency Use Authorization (EUA)|url=https://www.fda.gov/media/150319/download|url-status=live|archive-url=https://web.archive.org/web/20211125042744/https://www.fda.gov/media/150319/download|archive-date=25 November 2021|access-date=31 July 2021|website=U.S. [[Food_and_Drug_Administration|Food and Drug Administration]] (FDA)|format=PDF}</ref>。
                                                                     
== 医疗性使用 ==
本药每月通过静脉注射施用。每次注射约一小时。<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=de}}</ref>2013年10月本药[[皮下注射|皮下注射]]制剂获得批准。<ref>{{cite news|url=http://www.gene.com/media/press-releases/14557/2013-10-21/genentech-gains-fda-approval-for-new-sub |archive-url=https://web.archive.org/web/20170908020357/http://www.gene.com/media/press-releases/14557/2013-10-21/genentech-gains-fda-approval-for-new-sub |archive-date=8 September 2017 |title=Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis|publisher=Genentech|date=21 October 2013}}</ref>

=== 类风湿关节炎 ===
本药在{{link-en|改善病情抗风湿药|disease-modifying antirheumatic drug}}与{{link-en|肿瘤坏死因子抑制剂|TNF inhibitor|肿瘤坏死因子-α抑制剂}}无效或不耐受时与[[氨甲蝶呤|氨甲蝶呤]]联合使用治疗中重症类风湿关节炎。本药亦可在病人不耐受氨甲蝶呤时单独使用。<ref name="R090105">{{cite press release
 |title       = RoActemra approved in Europe to treat patients suffering from Rheumatoid Arthritis
 |publisher   = [[Hoffmann–La_Roche|Hoffmann–La Roche]]
 |date        = 2009-01-21
 |url         = http://www.roche.com/media/media_releases/med-cor-2009-01-21.htm
 |access-date  = 2009-01-05
 |url-status     = dead
 |archive-url  = https://web.archive.org/web/20090228170605/http://www.roche.com/media/media_releases/med-cor-2009-01-21.htm
 |archive-date = 2009-02-28
}}</ref><ref name="RoActemra">{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000955/WC500111086.pdf|title=Assessment report for RoActemra|publisher=European Medicines Agency|access-date=2021-02-25|archive-date=2016-01-19|archive-url=https://web.archive.org/web/20160119063056/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000955/WC500111086.pdf|dead-url=no}}</ref>

本药可减缓疾病恶化，改善病人身体活动功能。<ref>{{Cite journal|title=LITHE: Tocilizumab Inhibits Radiographic Progression and Improves Physical Function in Rheumatoid Arthritis (RA) Patients (Pts) at 2 Yrs with Increasing Clinical Efficacy Over Time|author=Roy Fleischmann|publisher=ACR|year=2009|url=https://acr.confex.com/acr/2009/webprogram/Paper15221.html|display-authors=etal|access-date=2021-02-25|archive-date=2020-08-09|archive-url=https://web.archive.org/web/20200809125820/https://acr.confex.com/acr/2009/webprogram/Paper15221.html|dead-url=no}}</ref>

=== 幼年特发性关节炎 ===
除不耐受情况外，本药与氨甲蝶呤联合使用治疗[[幼年特发性关节炎|幼年特发性关节炎]]，与类风湿关节炎疗法类似。有证据证明本药对两岁以上儿童一般安全有效。<ref>{{cite journal|url=https://acrabstracts.org/wp-content/uploads/2018/06/2010_ACR_ARHP_Abstract_Supplement.pdf#page=604&zoom=auto,-67,314|title=Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: Efficacy Data From the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial|journal=Arthritis & Rheumatism|year=2010|volume=62|issue=Supplement 10|page=1434|last1=Chaitow|first1=J|last2=De Benedetti|first2=F|last3=Brunner|first3=H|last4=Ruperto|first4=N|display-authors=3|access-date=2021-02-25|archive-date=2019-12-31|archive-url=https://web.archive.org/web/20191231153652/https://acrabstracts.org/wp-content/uploads/2018/06/2010_ACR_ARHP_Abstract_Supplement.pdf#page=604&zoom=auto,-67,314|dead-url=no}}</ref>

2011年[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）批准使用本药治疗活动期全身型幼年特发性关节炎。活动期全身型幼年特发性关节炎是一种影响儿童的罕见关节炎。<ref name="Genentech_actemra_2011">{{citation |url=http://www.gene.com/media/press-releases/13347/2011-04-15/fda-approves-actemra-tocilizumab-for-the |archive-url=https://web.archive.org/web/20181001232821/http://www.gene.com/media/press-releases/13347/2011-04-15/fda-approves-actemra-tocilizumab-for-the |archive-date=1 October 2018 |date=April 15, 2011 |access-date=July 20, 2015 |title=FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) |location=South San Francisco, California |publisher=Genentech}}</ref>

=== 卡斯尔曼氏病 ===
本药在日本获准治疗罕见B细胞良性肿瘤[[卡斯尔曼氏病|卡斯尔曼氏病]]。<ref name ="R090105"/><ref name="pmid17541233">{{Cite journal|title=Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease|url=https://pubmed.ncbi.nlm.nih.gov/17541233|last=Matsuyama|first=Masashi|last2=Suzuki|first2=Takeshi|date=2007|journal=Internal Medicine (Tokyo, Japan)|issue=11|doi=10.2169/internalmedicine.46.6262|volume=46|pages=771–774|issn=1349-7235|pmid=17541233|last3=Tsuboi|first3=Hiroto|last4=Ito|first4=Satoshi|last5=Mamura|first5=Mizuko|last6=Goto|first6=Daisuke|last7=Matsumoto|first7=Isao|last8=Tsutsumi|first8=Akito|last9=Sumida|first9=Takayuki|access-date=2021-05-09|archive-date=2021-02-28|archive-url=https://web.archive.org/web/20210228155109/https://pubmed.ncbi.nlm.nih.gov/17541233/|dead-url=no}}</ref>

=== 视神经脊髓炎 ===

初步报告显示本药可能对难治性{{link-en|视神经脊髓炎谱系疾病|Neuromyelitis optica spectrum disorder|视神经脊髓炎}}有效。<ref>{{Cite journal|title=Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report|url=https://pubmed.ncbi.nlm.nih.gov/24313919|last=Komai|first=Toshihiko|last2=Shoda|first2=Hirofumi|date=2016|journal=Modern Rheumatology|issue=2|doi=10.3109/14397595.2013.861333|volume=26|pages=294–296|issn=1439-7609|pmid=24313919|last3=Yamaguchi|first3=Kenichi|last4=Sakurai|first4=Keiichi|last5=Shibuya|first5=Mihoko|last6=Kubo|first6=Kanae|last7=Takahashi|first7=Toshiyuki|last8=Fujio|first8=Keishi|last9=Yamamoto|first9=Kazuhiko|access-date=2021-05-09|archive-date=2021-05-12|archive-url=https://web.archive.org/web/20210512151116/https://pubmed.ncbi.nlm.nih.gov/24313919/|dead-url=no}}</ref><ref>{{Cite journal|title=Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica: Implication for Cellular Immune Responses|url=http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2013.668|last=Kieseier|first=Bernd C.|last2=Stüve|first2=Olaf|date=2013-03-01|journal=JAMA Neurology|issue=3|doi=10.1001/jamaneurol.2013.668|volume=70|pages=390|language=en|issn=2168-6149|last3=Dehmel|first3=Thomas|last4=Goebels|first4=Norbert|last5=Leussink|first5=Verena I.|last6=Mausberg|first6=Anne K.|last7=Ringelstein|first7=Marius|last8=Turowski|first8=Bernd|last9=Aktas|first9=Orhan}}</ref><ref>{{Cite journal|title=Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy|url=http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2013.1246|last=Ayzenberg|first=Ilya|last2=Kleiter|first2=Ingo|date=2013-03-01|journal=JAMA Neurology|issue=3|doi=10.1001/jamaneurol.2013.1246|volume=70|pages=394|language=en|issn=2168-6149|last3=Schröder|first3=Alexandra|last4=Hellwig|first4=Kerstin|last5=Chan|first5=Andrew|last6=Yamamura|first6=Takashi|last7=Gold|first7=Ralf}}</ref><ref>{{Cite journal|title=Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab|url=http://www.tandfonline.com/doi/full/10.3109/s10165-012-0715-9|last=Araki|first=Manabu|last2=Aranami|first2=Toshimasa|date=2013-07-XX|journal=Modern Rheumatology|issue=4|doi=10.3109/s10165-012-0715-9|volume=23|pages=827–831|language=en|issn=1439-7595|pmc=PMC3713263|pmid=22782533|last3=Matsuoka|first3=Takako|last4=Nakamura|first4=Masakazu|last5=Miyake|first5=Sachiko|last6=Yamamura|first6=Takashi}}</ref>

=== 巨细胞动脉炎 ===

2017年5月FDA批准本药治疗[[巨细胞动脉炎|巨细胞动脉炎]]。<ref>{{Cite web|url=https://www.drugs.com/newdrugs/fda-approves-actemra-tocilizumab-subcutaneous-giant-cell-arteritis-4535.html|title=FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis|website=Drugs.com|access-date=2021-02-25|archive-date=2020-08-09|archive-url=https://web.archive.org/web/20200809205055/https://www.drugs.com/newdrugs/fda-approves-actemra-tocilizumab-subcutaneous-giant-cell-arteritis-4535.html|dead-url=no}}</ref>

=== 细胞因子释放综合征 ===
2017年8月30日FDA批准本药治疗[[嵌合抗原受体T细胞|嵌合抗原受体T细胞]]疗法导致的[[细胞因子释放综合征|细胞因子释放综合征]]。<ref>{{cite web|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574154.htm?platform=hootsuite|title=FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome|date=30 August 2017|publisher=[[US_FDA|US FDA]]|access-date=2021-02-25|archive-date=2021-08-29|archive-url=https://web.archive.org/web/20210829090235/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome?platform=hootsuite|dead-url=no}}</ref>

=== 2019冠状病毒病 ===
2019冠状病毒病（COVID-19）中急性肺损伤的发病机理与过度发炎有关，此时细胞介素（IL-6、IL-1、IL-2、TNF-α）水平高。<ref>{{cite journal | vauthors = Shoenfeld Y | title = Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning | journal = Autoimmunity Reviews | volume = 19 | issue = 6 | pages = 102538 | date = June 2020 | pmid = 32268212 | pmc = 7131471 | doi = 10.1016/j.autrev.2020.102538 | url = https://linkinghub.elsevier.com/retrieve/pii/S1568997220300938 | access-date = 2021-02-25 | archive-date = 2020-07-23 | archive-url = https://web.archive.org/web/20200723072319/https://linkinghub.elsevier.com/retrieve/pii/S1568997220300938 | dead-url = no }}</ref><ref name=":0" />初步试验数据显示本药可能有效改善重症患者疗效结果；REMAP-CAP试验提供了足够证据以批准本药。<ref name="BBC News">{{Cite news|date=2020-11-19|title=Tocilizumab: Arthritis drug may treat severe Covid|language=en-GB|work=BBC News|url=https://www.bbc.co.uk/news/health-55002339|access-date=2020-11-19|archive-date=2021-01-27|archive-url=https://web.archive.org/web/20210127014955/https://www.bbc.co.uk/news/health-55002339|dead-url=no}}</ref><ref name="BBCNew 55574662">{{Cite news|first=Michelle|last=Roberts|date=2021-01-07|title=Two more life-saving Covid drugs discovered|language=en-GB|work=BBC News|url=https://www.bbc.co.uk/news/health-55574662|access-date=2021-01-07|archive-date=2021-01-28|archive-url=https://web.archive.org/web/20210128192227/https://www.bbc.co.uk/news/health-55574662|dead-url=no}}</ref>

== 不良反应 ==
临床试验中最常见的不良反应是[[上呼吸道感染|上呼吸道感染]]（超过10%）、[[急性鼻咽炎|急性鼻咽炎]]（感冒）、头疼、高血压（至少5%）。至少5%病例[[谷丙转氨酶|谷丙转氨酶]]水平增高，绝大部分无症状。亦常见血胆固醇水平增高。<ref>{{Cite journal|title=Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study|url=https://pubmed.ncbi.nlm.nih.gov/18821691|last=Genovese|first=Mark C.|last2=McKay|first2=James D.|date=2008-10|journal=Arthritis and Rheumatism|issue=10|doi=10.1002/art.23940|volume=58|pages=2968–2980|issn=0004-3591|pmid=18821691|last3=Nasonov|first3=Evgeny L.|last4=Mysler|first4=Eduardo F.|last5=da Silva|first5=Nilzio A.|last6=Alecock|first6=Emma|last7=Woodworth|first7=Thasia|last8=Gomez-Reino|first8=Juan J.|access-date=2021-05-09|archive-date=2021-09-02|archive-url=https://web.archive.org/web/20210902200814/https://pubmed.ncbi.nlm.nih.gov/18821691/|dead-url=no}}</ref>不常见副作用包括眩晕、感染、皮肤或黏膜疹、[[胃炎|胃炎]]、[[口腔溃疡|口腔溃疡]]。罕见的严重反应包括[[肠胃穿孔|肠胃穿孔]]（六个月中0.26%）、[[过敏性休克|过敏性休克]]（0.2%）。<ref name="Arzneistoff-Profile">{{cite book|title=Arzneistoff-Profile|editor=Dinnendahl, V |editor2=Fricke, U|publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|year=2010|edition=23|volume=4|isbn=978-3-7741-9846-3|language=de}}</ref>

== 相互作用 ==

本药无确切的相互作用。注射本药一剂后血浆[[辛伐他汀|辛伐他汀]]水平降低57%；该现象尚不清楚是否有临床价值。该现象可能由类风湿关节炎患者IL-6水平升高后抑制[[细胞色素P450|细胞色素P450]]酶（[[CYP1A2|CYP1A2]]、[[CYP2C9|CYP2C9]]、[[CYP2C19|CYP2C19]]、[[CYP3A4|CYP3A4]]）合成导致：本药降低IL-6水平后使细胞色素水平恢复，提高辛伐他汀代谢。<ref name="Arzneistoff-Profile" />

== 作用机理 ==
[[白细胞介素-6|白细胞介素-6]]（IL-6）参与免疫和炎症反应。类风湿关节炎等[[自体免疫疾病|自体免疫疾病]]与异常高水平IL-6有关。托珠单抗可与可溶IL-6受体结合，亦可与细胞膜上的IL-6受体结合，阻止IL-6的促炎症作用。<ref name="Arzneistoff-Profile" /><ref>{{Cite journal|title=Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study|url=https://ard.bmj.com/lookup/doi/10.1136/ard.2008.105197|last=Jones|first=G|last2=Sebba|first2=A|date=2010-01-XX|journal=Annals of the Rheumatic Diseases|issue=01|doi=10.1136/ard.2008.105197|volume=69|pages=88–96|language=en|issn=0003-4967|pmc=PMC3747519|pmid=19297346|last3=Gu|first3=J|last4=Lowenstein|first4=M B|last5=Calvo|first5=A|last6=Gomez-Reino|first6=J J|last7=Siri|first7=D A|last8=Tomšič|first8=M|last9=Alecock|first9=E}}</ref>可溶IL-6受体与细胞膜上IL-6受体在类风湿关节炎发病过程的作用可能不同；可溶IL-6受体可能与疾病恶化有关。<ref>{{Cite journal|title=The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases|url=https://pubmed.ncbi.nlm.nih.gov/12421676|last=Kallen|first=Karl-Josef|date=2002-11-11|journal=Biochimica Et Biophysica Acta|issue=3|doi=10.1016/s0167-4889(02)00325-7|volume=1592|pages=323–343|issn=0006-3002|pmid=12421676|access-date=2021-05-09|archive-date=2021-02-09|archive-url=https://web.archive.org/web/20210209154247/https://pubmed.ncbi.nlm.nih.gov/12421676/|dead-url=no}}</ref>

== 历史 ==
[[岸本忠三|岸本忠三]]于二十世纪八十年代在[[大阪大学|大阪大学]]发现并克隆了白介素-6与其受体。[[中外制药|中外制药]]于1997年为治疗类风湿关节炎开发本药。治疗卡斯尔曼氏病与幼年特发性关节炎的临床试验分别在2001年和2002年开始。罗氏根据2003年授权协议共同开发本药。<ref name="KPJ">{{cite web|url=http://www.krankenpflege-journal.com/rheuma/768-die-entwicklung-von-tocilizumab-medizinischer-fortschritt-auf-basis-einer-erfolgreichen-kooperation-von-chugai-und-roche.html |archive-url=https://web.archive.org/web/20181015051035/http://www.krankenpflege-journal.com/rheuma/768-die-entwicklung-von-tocilizumab-medizinischer-fortschritt-auf-basis-einer-erfolgreichen-kooperation-von-chugai-und-roche.html |archive-date=15 October 2018 |language=de|title=Die Entwicklung von Tocilizumab|trans-title=The development of tocilizumab|author=Markus Harwart|year=2008|publisher=Krankenpflege-Journal}}</ref>

2008年数据显示了本药和氨甲蝶呤联合使用时治疗类风湿关节炎的效力。<ref>{{Cite web|url=http://news.bbc.co.uk/2/hi/health/7692701.stm|title=Jab hope for rheumatoid arthritis|date=October 27, 2008|via=news.bbc.co.uk|access-date=2021-02-25|archive-date=2021-01-26|archive-url=https://web.archive.org/web/20210126125411/http://news.bbc.co.uk/2/hi/health/7692701.stm|dead-url=no}}</ref>进一步研究发现本药在单独用药和与传统改善病情抗风湿药联合使用时对治疗中重症成年类风湿关节炎患者都有效，且耐受性一般较好。<ref name="tociliz">{{cite journal | vauthors = Oldfield V, Dhillon S, Plosker GL | title = Tocilizumab: a review of its use in the management of rheumatoid arthritis | journal = Drugs | volume = 69 | issue = 5 | pages = 609–32 | year = 2009 | pmid = 19368420 | doi = 10.2165/00003495-200969050-00007 | url = http://adisonline.com/drugs/abstract/2009/69050/Tocilizumab__A_Review_of_its_Use_in_the_Management.7.aspx | url-status = dead | archive-url = https://archive.today/20130116072127/http://adisonline.com/drugs/abstract/2009/69050/Tocilizumab__A_Review_of_its_Use_in_the_Management.7.aspx | archive-date = 2013-01-16 | access-date = 2021-02-25 }}</ref>

2005年6月本药在日本获准治疗卡斯尔曼氏病。<ref name="R090105" />2009年1月[[欧洲药品管理局|欧洲药品管理局]]（EMA）以商品名RoActerma批准在一定限制下以本药治疗类风湿关节炎。2010年1月11日FDA以相同用途按商品名Actemra批准本药。<ref>{{cite news|url=https://online.wsj.com/article/BT-CO-20100111-701072.html?mod=WSJ_World_MIDDLEHeadlinesAsia |title=Roche: FDA Approves Actemra For Rheumatoid Arthritis |newspaper=The Wall Street Journal |date=11 January 2010 |url-status=dead |archive-url=https://web.archive.org/web/20100114015725/http://online.wsj.com/article/BT-CO-20100111-701072.html?mod=WSJ_World_MIDDLEHeadlinesAsia |archive-date=January 14, 2010 }}</ref>2009年5月27日{{link-en|澳大利亚药品管理局|Therapeutic Goods Administration}}批准本药。<ref name="TGA">{{cite web|url=http://www.tga.gov.au/docs/html/adec/adec0263.htm |archive-url=https://web.archive.org/web/20090820225127/http://www.tga.gov.au/docs/html/adec/adec0263.htm |archive-date=20 August 2009 |title=Australian Drug Evaluation Committee 263rd meeting resolutions|publisher=Therapeutic Goods Administration|date=27 May 2009}}</ref>本药在2010年8月1日列入{{link-en|澳大利亚药物福利计划|Pharmaceutical Benefits Scheme}}。<ref name="PBS">{{cite web|url=http://www.nps.org.au/health_professionals/publications/nps_radar/2010/august_2010/brief_item_anakinra|title=Anakinra (Kineret) to be deleted from the PBS|publisher=National Prescribing Service Limited|date=1 August 2010|url-status=dead|archive-url=https://web.archive.org/web/20120603095255/http://www.nps.org.au/health_professionals/publications/nps_radar/2010/august_2010/brief_item_anakinra|archive-date=3 June 2012}}</ref>2009年7月新西兰批准配送本药。<ref>{{cite journal |last1= Richards |first1= Mark |date= 20 July 2009 |title= Consent to the Distribution of New Medicines |journal= [[New_Zealand_Gazette|New Zealand Gazette]] |volume= 2009 |issue= 105 |pages= 2418 |url= https://gazette.govt.nz/notice/id/2009-go6204 |access-date= 9 June 2015 |archive-date= 2020-08-09 |archive-url= https://web.archive.org/web/20200809100935/https://gazette.govt.nz/notice/id/2009-go6204 |dead-url= no }}</ref>2013年7月1日{{link-en|新西兰药品管理局|Pharmaceutical Management Agency}}（Pharmac）批准为本药治疗幼年特发性关节炎时提供补贴。<ref>{{cite web |title= Approval of proposal involving pegfilgrastim and tocilizumab |date= 24 May 2013 |url= http://www.pharmac.health.nz/assets/notification-2013-05-24-pegfilgrastim-and-tocilizumab.pdf |publisher= Pharmaceutical Management Agency |access-date= 9 June 2015}}</ref>2014年7月1日Pharmac亦批准对本药治疗类风湿关节炎进行补贴。<ref>{{cite web |title= Decision to widen access to tocilizumab (Actemra) for rheumatoid arthritis in patients who are unable to be treated with methotrexate |date= 14 May 2014 |url= http://www.pharmac.health.nz/assets/notification-2014-05-14-tocilizumab.pdf |publisher= Pharmaceutical Management Agency |access-date= 9 June 2015}}</ref><!-- 2011年4月FDA批准本药治疗两岁以上幼年特发性关节炎患儿，同年8月EMA也批准该用途。-->

中外制药在日本和其他亚洲国家经销本药。罗氏与中外制药在英国、法国、德国等国家合作营销本药。<ref name="KPJ" />

== 研究 ==

[[卵巢癌|卵巢癌]]病人癌细胞中IL-6水平与不良预后相关；抗IL-6抗体{{link-en|司妥昔单抗|siltuximab}}能降低体外培养细胞IL-6信号通路强度，亦在[[动物模型|动物模型]]中显示积极影响；然而司妥昔单抗在{{link-en|临床试验阶段|phases of clinical research|二期临床试验}}中对晚期卵巢癌病理无明确作用。<ref name="Coward2011">{{cite journal | vauthors = Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR | display-authors = 6 | title = Interleukin-6 as a therapeutic target in human ovarian cancer | journal = Clinical Cancer Research | volume = 17 | issue = 18 | pages = 6083–96 | date = September 2011 | pmid = 21795409 | pmc = 3182554 | doi = 10.1158/1078-0432.CCR-11-0945 }}</ref>试验人员随后发现高分化卵巢癌细胞中抗IL-6抗体降低IL-6的主要下游转录因子[[STAT3|STAT3]]水平，进而增加[[表皮生长因子受体|表皮生长因子受体]]（EGFR）通路活性；EGFR通路活性增加可能是若干癌症疗法中产生抗药性的原因。<ref name="Milagre2015">{{cite journal | vauthors = Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR | display-authors = 6 | title = Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer | journal = Cancer Research | volume = 75 | issue = 7 | pages = 1255–64 | date = April 2015 | pmid = 25670170 | pmc = 4384986 | doi = 10.1158/0008-5472.CAN-14-1801 }}</ref>研究人员还显示使用[[吉非替尼|吉非替尼]]抑制EGFR通路时可抑制培养细胞和动物模型中肿瘤增生。<ref name="Milagre2015"/>

有试验用本药治疗[[肺高压|肺高压]]。<ref name="Roche-NIHR" >{{cite web|url=http://www.pharmatimes.com/Article/16-01-06/Roche_links_with_UK_gov_for_ground-breaking_PAH_trial.aspx|title=Roche links with UK gov for ground-breaking PAH trial|publisher=PharmaTimes Media Ltd|date=2016-01-06|access-date=2021-02-25|archive-date=2016-03-06|archive-url=https://web.archive.org/web/20160306063812/http://www.pharmatimes.com/Article/16-01-06/Roche_links_with_UK_gov_for_ground-breaking_PAH_trial.aspx|dead-url=no}}</ref>有一用本药防治心脏移植后急性细胞性肺排斥的多中心临床试验。<ref>{{ClinicalTrialsGov|NCT03644667|Tocilizumab in Cardiac Transplantation}}</ref>

=== COVID-19 ===
中国[[中华人民共和国国家卫生健康委员会|国家卫生健康委员会]]（卫健委）将本药列入[[2019冠状病毒病|COVID-19]]病人治疗指南。<ref>{{Cite news|title=China approves use of Roche drug in battle against coronavirus complications|url=https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg-idUSKBN20R0LF|newspaper=Reuters|date=2020-03-04|accessdate=2021-05-09|language=en|first=Roxanne Liu, John|last=Miller|archive-date=2020-03-05|archive-url=https://web.archive.org/web/20200305035003/https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg-idUSKBN20R0LF|dead-url=no}}</ref>2020年3月中国批准使用本药治疗COVID-19病人炎症反应。{{as of|2020|6}}上不存在该疗法有效的证据。<ref>{{cite news|url=https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF|title=China approves use of Roche arthritis drug for coronavirus patients|date=2020-03-04|work=Reuters|accessdate=2021-02-25|archive-date=2020-03-12|archive-url=https://web.archive.org/web/20200312204625/https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF|dead-url=no}}</ref>卫健委表示仅有21个病人使用本药。<ref>{{cite news |url=https://www.ilfattoquotidiano.it/2020/03/09/coronavirus-farmaco-per-curare-lartrite-reumatoide-efficace-su-due-pazienti-con-polmonite-severa-da-covid-19/5730553/ |title=Coronavirus, farmaco per curare l'artrite reumatoide efficace su due pazienti con polmonite severa da Covid 19 |trans-title=Coronavirus, drug to treat rheumatoid arthritis effective on two patients with severe pneumonia from Covid 19 |date=2020-03-09 |publisher=Il fatto quotidiano |language=it |accessdate=2021-02-25 |archive-date=2020-08-09 |archive-url=https://web.archive.org/web/20200809101148/https://www.ilfattoquotidiano.it/2020/03/09/coronavirus-farmaco-per-curare-lartrite-reumatoide-efficace-su-due-pazienti-con-polmonite-severa-da-covid-19/5730553/ |dead-url=no }}</ref> 同月在中国进行了对比本药与[[法匹拉韦|法匹拉韦]]单独使用及两药联合使用效力的11中心随机试验。<ref>{{Cite web|url=https://www.clinicaltrials.gov/ct2/show/NCT04310228|title=Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019|date=March 17, 2020|publisher=National Library of Medicine|access-date=2021-02-25|archive-date=2021-02-25|archive-url=https://web.archive.org/web/20210225061444/https://clinicaltrials.gov/ct2/show/NCT04310228|dead-url=no}}</ref>

2020年3月11日意大利医生保罗·阿谢尔托报告本药在意大利三例重症COVID-19中显示有效。<ref>{{Cite web|url=http://www.ansa.it/english/news/general_news/2020/03/13/3-patients-get-better-on-arthritis-drug_90d4764d-d93f-463e-ab07-168b34b084d0.html|title=3 patients get better on arthritis drug - English|date=March 13, 2020|work=ANSA.it|access-date=2021-02-25|archive-date=2020-03-19|archive-url=https://web.archive.org/web/20200319022045/http://www.ansa.it/english/news/general_news/2020/03/13/3-patients-get-better-on-arthritis-drug_90d4764d-d93f-463e-ab07-168b34b084d0.html|dead-url=no}}</ref>2020年3月14日[[那不勒斯|那不勒斯]]六名接受治疗患者中三名病情改善；意大利药品管理局因此将试验扩大到另外五家医院。<ref>{{Cite web|url=https://www.ilmessaggero.it/italia/coronavirus_farmaco_artrite_ultime_notizie_news_napoli-5109045.html|title=Coronavirus, via libera dell'Aifa al farmaco anti-artrite efficace su 3 pazienti e a un antivirale: test in 5 centri|work=www.ilmessaggero.it|language=it|access-date=2020-03-14|archive-date=2020-03-19|archive-url=https://web.archive.org/web/20200319022047/https://www.ilmessaggero.it/italia/coronavirus_farmaco_artrite_ultime_notizie_news_napoli-5109045.html|dead-url=no}}</ref>罗氏与世界卫生组织（WHO）分别发起本药对重症COVID-19病例的试验。<ref>{{Cite news|url=https://www.swissinfo.ch/eng/covid-19_who-and-roche-launch-trials-of-potential-coronavirus-treatments/45630498|title=WHO and Roche launch trials of potential coronavirus treatments|work=SwissInfo.Ch|accessdate=2021-02-25|archive-date=2020-03-21|archive-url=https://web.archive.org/web/20200321134640/https://www.swissinfo.ch/eng/covid-19_who-and-roche-launch-trials-of-potential-coronavirus-treatments/45630498|dead-url=no}}</ref>

在美国重要医院中进行的研究发现COVID-19住院病人中常见肝功能指标异常；该异常与不良临床结果相关；该研究提及的COVID-19治疗用药包括本药。<ref>{{Cite journal|title=Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network|url=https://pubmed.ncbi.nlm.nih.gov/32725890|last=Hundt|first=Melanie A.|last2=Deng|first2=Yanhong|date=2020-10|journal=Hepatology (Baltimore, Md.)|issue=4|doi=10.1002/hep.31487|volume=72|pages=1169–1176|issn=1527-3350|pmid=32725890|last3=Ciarleglio|first3=Maria M.|last4=Nathanson|first4=Michael H.|last5=Lim|first5=Joseph K.|access-date=2021-05-09|archive-date=2021-08-11|archive-url=https://web.archive.org/web/20210811104920/https://pubmed.ncbi.nlm.nih.gov/32725890/|dead-url=no}}</ref>该研究发现COVID-19治疗所用若干种药与肝转氨酶水平超过正常范围上限（ULN）五倍以上有关；该指标异常可能是由疾病本身导致，亦可能由药物导致该研究作者，耶鲁大学肝脏中心主任迈克尔·内桑森表示会进行进一步研究已确定转氨酶异常的原因。<ref>{{Cite web|title=Strong link found between abnormal liver tests and poor COVID-19 outcomes|url=https://news.yale.edu/2020/08/06/strong-link-found-between-abnormal-liver-tests-and-poor-covid-19-outcomes|access-date=2021-05-09|date=2020-08-06|last=Belli|first=Brita|work=YaleNews|language=en|archive-date=2020-12-31|archive-url=https://web.archive.org/web/20201231112236/https://news.yale.edu/2020/08/06/strong-link-found-between-abnormal-liver-tests-and-poor-covid-19-outcomes|dead-url=no}}</ref>

2020年7月29日罗氏宣布在其随机双盲试验中发现本药可缩短COVID-19肺炎病人住院时间。然而本药并不能改善肺炎症状或降低病人死亡率。<ref name=":0">{{Cite web|date=29 July 2020|title=Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalized patients with severe COVID-19 associated pneumonia|url=https://www.roche.com/media/releases/med-cor-2020-07-29.htm|access-date=2020-08-18|work=www.roche.com|language=en|archive-date=2021-01-09|archive-url=https://web.archive.org/web/20210109093737/https://www.roche.com/media/releases/med-cor-2020-07-29.htm|dead-url=no}}</ref><ref>{{Cite journal|title=Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review|url=https://linkinghub.elsevier.com/retrieve/pii/S1568997220301312|last=Alijotas-Reig|first=Jaume|last2=Esteve-Valverde|first2=Enrique|date=2020-07-XX|journal=Autoimmunity Reviews|issue=7|doi=10.1016/j.autrev.2020.102569|volume=19|pages=102569|language=en|pmc=PMC7252146|pmid=32376394|last3=Belizna|first3=Cristina|last4=Selva-O'Callaghan|first4=Albert|last5=Pardos-Gea|first5=Josep|last6=Quintana|first6=Angela|last7=Mekinian|first7=Arsene|last8=Anunciacion-Llunell|first8=Ariadna|last9=Miró-Mur|first9=Francesc|access-date=2021-02-25|archive-date=2020-10-15|archive-url=https://web.archive.org/web/20201015045453/https://linkinghub.elsevier.com/retrieve/pii/S1568997220301312|dead-url=no}}</ref>

2020年10月另一项研究结论认为本药不能改善中度症状病人的死亡率或插管率。<ref>{{Cite journal|title=Efficacy of Tocilizumab in Patients Hospitalized with Covid-19|url=http://www.nejm.org/doi/10.1056/NEJMoa2028836|last=Stone|first=John H.|last2=Frigault|first2=Matthew J.|date=2020-12-10|journal=New England Journal of Medicine|issue=24|doi=10.1056/NEJMoa2028836|volume=383|pages=2333–2344|language=en|issn=0028-4793|pmc=PMC7646626|pmid=33085857|last3=Serling-Boyd|first3=Naomi J.|last4=Fernandes|first4=Ana D.|last5=Harvey|first5=Liam|last6=Foulkes|first6=Andrea S.|last7=Horick|first7=Nora K.|last8=Healy|first8=Brian C.|last9=Shah|first9=Ruta|access-date=2021-05-09|archive-date=2021-08-29|archive-url=https://web.archive.org/web/20210829090235/https://www.nejm.org/doi/10.1056/NEJMoa2028836|dead-url=no}}</ref>

2020年11月由[[伦敦帝国学院|伦敦帝国学院]]、加护审计与研究中心、[[乌得勒支大学|乌得勒支大学]]联合进行的REMAP-CAP试验发布新闻稿宣布本药对COVID-19重症病人有乐观效果。<ref>{{Cite news|last=Sample|first=Ian|date=2020-11-19|title=Rheumatoid arthritis drug appears to help Covid patients in ICU|language=en-GB|work=The Guardian|url=https://www.theguardian.com/world/2020/nov/19/rheumatoid-arthritis-drug-tocilizumab-appears-to-help-covid-patients-in-icu|access-date=2020-11-19|issn=0261-3077|archive-date=2021-02-12|archive-url=https://web.archive.org/web/20210212002133/https://www.theguardian.com/world/2020/nov/19/rheumatoid-arthritis-drug-tocilizumab-appears-to-help-covid-patients-in-icu|dead-url=no}}</ref><ref>{{Cite web|title=Initial data shows arthritis drug is effective in treating sickest Covid-19 patients|url=https://www.imperial.nhs.uk/about-us/news/initial-data-shows-arthritis-drug-is-effective-in-treating-sickest-covid-19-patients|access-date=2020-11-19|work=www.imperial.nhs.uk|language=en|archive-date=2020-11-29|archive-url=https://web.archive.org/web/20201129012812/https://www.imperial.nhs.uk/about-us/news/initial-data-shows-arthritis-drug-is-effective-in-treating-sickest-covid-19-patients|dead-url=no}}</ref>

2021年1月REMAP-CAP试验发表初步结论显示本药与{{link-en|沙利姆单抗|sarilumab}}可降低COVID-19重症病人死亡率。英国亦将本药列为COVID-19治疗推荐用药列表。<ref name=BBCNew-55574662-1>{{cite web|url=https://www.nice.org.uk/advice/es33/chapter/Product-overview#likely-place-in-therapy|title="Product overview COVID-19 rapid evidence summary: Tocilizumab for COVID-19 Advice; NICE"|access-date=20 January 2020|archive-date=2021-01-18|archive-url=https://web.archive.org/web/20210118160806/https://www.nice.org.uk/advice/es33/chapter/Product-overview#likely-place-in-therapy|dead-url=no}}</ref>

== 參看 ==
* {{link-en|白细胞介素-6抑制药|Anti-IL-6}}

== 參考文獻 ==
{{Reflist|30em}}

== 外部連結 ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/tocilizumab | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Tocilizumab | access-date = 2021-02-25 | archive-date = 2021-02-12 | archive-url = https://web.archive.org/web/20210212074016/https://druginfo.nlm.nih.gov/drugportal/name/Tocilizumab | dead-url = no }}

{{Immunosuppressants}}
{{COVID-19}}
{{Portal bar | Medicine}}
{{Authority control}}

[[Category:免疫抑制药|Category:免疫抑制药]]
[[Category:罕用药|Category:罕用药]]